Loading...

ABVC ABVC BIOPHARMA INC Company Mergers 8-K Filing

BVC

BVC

ABVC BIOPHARMA INC

(ABVC)

2024 8-K

Show Summary

Show Summary

Equity Offerings

Equity Offerings

Notification of Compliance

Failure to Satisfy Listing ...

Decrease in Dividend Rate

Notice of Delisting or Fail...

Financial Correction

Financial Results

CFO Resignation

Nasdaq Extension

Capital Structure Changes

Q3 Financial Results

Capital Structure Changes

Nasdaq Compliance

Corporate Update

Q2 Financial Results

CFO Suspension and Press Re...

Licensing Agreement Amendment

Licensing Agreement with Fo...

Agreement with OncoX BioPharma

Securities Purchase Agreeme...

Termination of Agreement

Agreement with OncoX BioPharma

Agreement with OncoX BioPharma

Annual Meeting of Shareholders

Agreement with OncoX BioPharma

Licensing Agreement

Bylaws Amendment

Financial Results Press Rel...

Securities Purchase Agreeme...

Securities Purchase Agreeme...

Acquisition of Land in Taiwan

Amendment Filing

Securities Purchase Agreement

Annual Meeting Adjournment

Securities Purchase Agreement

Securities Purchase Agreement

Licensing Agreement for CNS...

Financial Results Announcement

Entry into Material Definit...

Cooperation Agreement

Shareholder Update

Material Definitive Agreements

Entry into Material Definit...

Securities Purchase Agreement

Management Change

Resignation of CSO

Presentation Update

Phase II Study Put on Hold

Annual Meeting Voting Results

Financial Results Disclosure

Securities Purchase Agreement

Delisting Notice

External Links:

ABVC Biopharma entered into a definitive agreement with OncoX BioPharma to grant them exclusive rights to develop and commercialize ABVC's BLEX 404 drug extract for pancreatic cancer treatment, with OncoX paying ABVC $6.25 million and potential royal

AI Assistant

ABVC BIOPHARMA INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.